Skip to main content
Download PDF
Download ePub

Alleviation of migraine related pain and anxiety by inhibiting calcium-stimulating AC1-dependent CGRP in the insula of adult rats

The Journal of Headache and Pain volume 25, Article number: 81 (2024) Cite this article

Abstract

Background

Recent animal and clinical findings consistently highlight the critical role of calcitonin gene-related peptide (CGRP) in chronic migraine (CM) and related emotional responses. CGRP antibodies and receptor antagonists have been approved for CM treatment. However, the underlying CGRP-related signaling pathways in the pain-related cortex remain poorly understood.

Methods

The SD rats were used to establish the CM model by dural infusions of inflammatory soup. Periorbital mechanical thresholds were assessed using von-Frey filaments, and anxiety-like behaviors were observed via open field and elevated plus maze tests. Expression of c-Fos, CGRP and NMDA GluN2B receptors was detected using immunofluorescence and western blotting analyses. The excitatory synaptic transmission was detected by whole-cell patch-clamp recording. A human-used adenylate cyclase 1 (AC1) inhibitor, hNB001, was applied via insula stereotaxic and intraperitoneal injections in CM rats.

Results

The insular cortex (IC) was activated in the migraine model rats. Glutamate-mediated excitatory transmission and NMDA GluN2B receptors in the IC were potentiated. CGRP levels in the IC significantly increased during nociceptive and anxiety-like activities. Locally applied hNB001 in the IC or intraperitoneally alleviated periorbital mechanical thresholds and anxiety behaviors in migraine rats. Furthermore, CGRP expression in the IC decreased after the hNB001 application.

Conclusions

Our study indicated that AC1-dependent IC plasticity contributes to migraine and AC1 may be a promising target for treating migraine in the future.

Peer Review reports

Background

Chronic pain exerts an enormous personal and economic burden, affecting more than 30% of people worldwide [1]. Recent reports based on global disease burden analysis show that migraine remains second among the causes of disability, and chronic migraine (CM) affects up to 2% of the global population with limited therapeutic solutions are available [2,3,4]. According to latest category of chronic pain, the CM is classified into nociplastic pain, the third category that is mechanistically distinct from nociceptive pain, which is caused by ongoing inflammation and damage of tissues, and neuropathic pain, which is caused by nerve damage [5]. The mechanisms that underlie nociplastic pain are not fully understood, but it is thought that augmented central nervous system (CNS) pain and sensory processing and altered pain modulation play prominent roles [5, 6].

The insular cortex (IC) plays an important role as a "hub station" in brain function [7]. It is involved at least in the regulation of emotion, addiction, cognition, taste and vestibular functions [8, 9]. An increasing number of studies have shown that the IC also participates in pain perceptions as the anterior cingulate cortex (ACC) does by influencing synaptic transmission, such as in neuropathic pain, inflammatory pain and phantom limb pain [10,11,12,13,14,15,16], which leading these two area into major cortical areas for regulating chronic pain perception, especially for neuropathic pain [17,18,19,20,21,22,23]. A brain functional imaging study also has shown that the number of years of CM is significantly correlated with the strength of functional connections between the anterior IC and the medial dorsal thalamus, as well as between the anterior IC and periaqueductal gray matter [24]. Besides, the insular cortical thickness in women with migraine did not thin with age as it does in healthy individuals [25]. Except for the clinical studies, Jia et al. found that different frequencies of inflammatory soup (IS)-induced migraine models of rats could cause altered functional connectivity of the IC, which also gave us a clue that the IC may have a potential role in the pathophysiology of migraine [26]. In addition, the IC is an important brain area involved in negative emotion regulation including anxiety and depression [7, 27, 28], which are very common comorbidities among patients with migraine [29, 30].

Our previous studies in naive mice found that bath application of calcitonin gene-related peptide (CGRP), a crucial biomarker in migraine progression, significantly enhanced the excitatory transmission in the ACC and the IC [31, 32], and some studies reported that GluN2B-containing N-methyl-D-aspartate (NMDA) receptors and adenylyl cyclase 1 (AC1) played key roles in chronic pain [16,17,18,19]. Liu et al. demonstrated that cortical excitatory transmission was significantly enhanced in the ACC of IS-induced migraine model rats, and applying a selective inhibitor of AC1, NB001 in the ACC, could alleviate migraine symptoms [33]. However, less information is available for investigating the synaptic mechanisms about the migraine in the IC under pathological conditions.

Therefore, in the current study, the inflammatory mediators were used to the dura mater of adult rats to establish CM models. We found that the expression of c-Fos and CGRP was increased, and the excitatory transmission as well as phosphorylation of GluN2B receptors in the IC was enhanced. A human-used selective AC1 inhibitor, hNB001, applied locally in the IC or intraperitoneally, showed significant alleviations in the periorbital mechanical threshold and related anxiety behaviors in the rats suffering CM. What’s more, the expression of CGRP in the IC was decreased after applying hNB001. Our study indicated that AC1-dependent IC plasticity contributes to migraine and AC1 may be a promising target for treating migraine in the future.

Methods

Animals

Male Sprague-Dawley (SD) rats (8-9 weeks old) were purchased from SiBeiFu Beijing Biotechnology Co., Ltd. (Beijing, China), and housed in a temperature (22-24°C), humidity (40-60%), and light (12 hours light/dark cycle) controlled environment with free access to food and water. The experimental procedures were approved by the Institutional Animal Care and Use Committee, Chinese People’s Liberation Army (PLA) General Hospital, following the Regulations for the Administration of Affairs Concerning Experimental Animals.

Chronic Migraine (CM) model

Rats were anesthetized with sodium pentobarbital (50 mg/kg) and then fixed in a stereotaxic frame. The scalp covering the dorsal surface was cut to expose the skull. A small hole (1 mm in diameter) was drilled at 1.5 mm to the right of the sagittal suture and 1.5 mm posterior to the bregma for the insertion of a cannula (1 mm in diameter and 1 mm in length; RWD Life Science, China). The dura mater was kept intact during the surgery. The cannula was then fixed with screws and dental cement, and the scalp skin was sutured, leaving only the cannula cap exposed. The rats were then housed individually for postoperative recovery for seven days. The CM model was established by stimulating the dura mater adjacent to the superior sagittal sinus with a “IS”. The IS contained bradykinin (2 mM), histamine (2 mM), serotonin (2 mM), and prostaglandin E2 (0.2 mM), and was dissolved in phosphate buffered saline (PBS) [34]. In awake rats, 10 μL of IS or PBS was infused into the dura mater through the cannula. The infusions were administered over five minutes, once daily, for a total of 14 times.

Intraperitoneal injection of hNB001

hNB001 is a chemo-synthetic compound (C12H20N6O, Mw=264.33 g/mol) obtained from Forevercheer Holding Ltd.Co. (Hong Kong, China) and is dissolved in normal saline (NS). Upon completion of the CM model, hNB001 (20 mg/kg) or NS was administered via intraperitoneal injection for three consecutive times, once daily.

Microinjection of hNB001 into the IC

Based on the CM model, cannulas (0.56 mm in diameter; RWD Life Science, China) were also placed in the bilateral IC (5.7 mm left/right, 0 mm anterior to the bregma, and 7.7 mm deep; RWD Life Science, China). The rats were individually housed for one week after the cannula placement. The rest of the operations were the same as the CM model. 1 μL hNB001(10 mg/ml) or NS was slowly injected into the bilateral IC with a microinjector (Hamilton, USA) over five minutes, once a day for three consecutive days. The treatment began on the Day 14, and dural infusion of IS was discontinued.

Experimental groups

A total of 92 rats were used in the current study. The groups were divided according to the type of drug and the method of administration. Firstly, based on the drug injected into the rat’s dura mater, the groups were divided into the IS group and the PBS group (n=20 rats/group, three rats of the IS group were excluded for statistical analysis due to the failure of the surgery or death during the modeling). Secondly, according to the drug received by the IC of the IS rats, the groups were divided into the hNB001 group and the NS group (n=14 rats/group). Finally, based on the type of drug injected intraperitoneally into the IS rats, the groups were divided into the i.p. hNB001 group and the i.p. NS group (n=12 rats/group).

Periorbital mechanical threshold test

The periorbital mechanical threshold was measured daily (Day 0-Day 17) using von-Frey filaments (1.0-26 g). Each rat was adapted in the plastic box for 30 minutes before the measurement. During the measurement, the von-Frey filament was applied perpendicularly to the periorbital skin until the filament bent, and was maintained for five seconds or until the rat showed a positive response. The positive response included head withdrawal, vocalization, and pawing at the filament [35]. Three different periorbital locations (lateral canthus, supraorbital and forehead) were stimulated with a filament. Record the weight of the filament when a positive reaction occurs at two or three stimulation points as periorbital mechanical threshold. Repeat this process three times. The filaments were changed from low to high scale. For rats that did not respond to the maximum filament strength (26 g), 26 g was recorded as their periorbital mechanical threshold.

Hot plate test

Adult rats were placed on the hot plate device (55±0.5°C), surrounded by four plexiglas walls (Cold Hot Plate, Bioseb, USA). The latency to either lick the hind paw or jump was recorded as heat pain thresholds. Before dural infusion, each rat was tested three times with a five-minutes interval between each trial to calculate the average latency, starting one day prior to intervention and repeated every other day. Rats were kept on the hot plate for no more than 20s to avoid thermal injury.

Behavioral tests

Behavioral studies were performed at set times. Before the experiment, the animals were adapted in the dark behavioral analysis room for at least three hours, with free access to food and water. The animals were placed in the apparatus, and video recording was conducted for five minutes. Within the IS group and the PBS group, rats were tested at the start of the experiment, and on the Day 7 and Day 14. The hNB001 group and NS group were tested before administration (Day 14) and after administration was completed (Day 17), similar to the i.p. hNB001 group and i.p. NS group.

The open field apparatus consisted of a circular black base (120 cm in diameter) surrounded by black walls (40 cm high). The inner chamber was a circle with a diameter of 90 cm, and the outer space was annular. At the beginning of the test, the rats were placed in the central area, facing away from the experimenter. The total distance traveled, the distance covered in the central area, the time spent in the central area, and the number of entries into the central area were recorded by an animal behavior trace analysis system (SuperMaze, Xinruan, China).

The elevated plus maze (EPM) apparatus consisted of two opposite open arms (50 cm x 10 cm) and two opposite closed arms (50 cm x 10 cm x 40 cm). The maze center had a 10 cm x 10 cm open area, and the maze was elevated 60 cm above the ground. At the start of the test, the rats were placed on the central platform of the EPM, facing one of the open arms. The total distance traveled, open arms distance, time spent in the open arms, and the number of entries into the open arms were recorded by the animal behavior trajectory analysis system (SuperMaze, Xinruan, China).

Immunofluorescence staining and counting

All target tissues were collected 24-28 hours after the last administration. After general anesthesia with sodium pentobarbital, the rats were perfused intracardially with 120 mL of 0.01 M PBS, followed by 120 mL of 4% paraformaldehyde (PFA). The whole brain tissues were fixed in 4% PFA at 4°C for 24 hours, and then dehydrated in 15% and 30% sucrose until the tissues sank to the bottom. The brain tissues were cut into 8 μm thick axial sections on a freezing microtome (Leica, Japan). The sections were permeabilized with 0.25% Triton X-100 mixed with 10% goat serum at room temperature, and then incubated with primary antibodies at 4°C overnight. The sections were washed three times with PBS, each for five minutes, and then incubated with species-specific fluorescently labeled secondary antibodies at 37°C for two hours. Finally, the nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, Abcam, ab104139, UK) and mounted. Images were acquired with an upright fluorescence microscope (NIKON ECLIPSE C1, Konni, Japan). The primary antibodies used for immunofluorescence staining were c-Fos (1:2000, cell signaling technology, #2250, USA), CGRP (1:2000, cell signaling technology, #14959, USA), and the secondary antibodies were anti-mouse/rabbit secondary antibodies (1:300, Servicebio, GB21301, GB21303, China). For the detection of positive cells, images were analyzed with ImageJ 1.53t software. Briefly, three regions of the same area were randomly selected in the ACC (0.96-0.72 mm anterior to the bregma), IC (0.24-0.48 mm posterior to the bregma), trigeminal nucleus caudalis (TNC, also known as Sp5c in rats atlas) (14.28-14.40 mm posterior to the bregma), and at 40 times magnification, the number of c-Fos and CGRP positive cells was counted, and then the average value was recorded as the final data.

Western blotting analysis

Protein preparation and western blotting analysis were performed according to a previous method [36]. Briefly, the bilateral IC brain tissues were collected and stored at -80°C until use. The rat brain tissues were ground at low temperature with a tissue grinder (Servicebio, China), and then fully lysed with RIPA lysis buffer (Beyotime, China) containing protease and phosphatase inhibitors (Beyotime, China). The supernatant was obtained after low-temperature centrifugation. The protein concentration was determined with a BCA kit (AQ, China). Protein (30 μg) was separated by SDS-PAGE gel and electrotransferred to polyvinyl difluoride (PVDF) membranes (Millipor, China). The PVDF membranes were blocked with a quick blocking solution (Yang Guang Bio, China) for one minute, and then incubated with the following antibodies: CGRP (1:1000, cell signaling technology, #14959, USA), GluN2B (1:2000, Proteintech, 21920-1-AP, China), p-GluN2B-S1303 (1:2000, abcam, ab81271, UK), AC1 (1:1000, abcam, ab69597, UK), β-actin (1:3000, Proteintech, HRP-66009, China), and anti-mouse/rabbit secondary antibodies (1:3000, Proteintech, SA00001-1, SA00001-2 China). The protein bands were visualized with the HRP ECL system, and then analyzed with ImageJ 1.53t software for the gray value.

Brain slices preparation

Coronal brain slices (300 μm) at the level of the IC were prepared using standard methods [31, 33, 37]. Briefly, rats were deeply anesthetized with 5% isoflurane and transcardially perfused with cold cutting solution containing (in mM) 2.5 KCl, 0.5 CaCl2, 10 MgSO4, 1.25 NaH2PO4, 2 thiourea, 3 sodium pyruvate, 92 N-methyl-D-glucamine, 20 N-(2-hydroxyethyl) piperazine-N’-2-ethanesulfonic acid (HEPES), 25 D-glucose, 5 L-ascorbic acid, and 30 NaHCO3(pH 7.35-7.40). Then the rats were sacrificed by decapitation and the whole brain was removed quickly from the skull and submerged in the oxygenated (95% O2 and 5% CO2) ice-cold cutting solution. The whole brain tissue was cooled for short time before trimmed as the proper part to glue onto the microslicer (VT1200S Vibratome, Leica, Germany). The coronal brain slices containing the IC were cut, and then incubated in a submerged recovery chamber with artificial cerebrospinal fluid (ACSF) containing (in mM) 124 NaCl, 2.5 KCl, 2 MgSO4, 1 NaH2PO4, 2 CaCl2, 25 NaHCO3, and 10 D-glucose at room temperature for 1 h. The ACSF was continuously aerated with a mixture of 95% O2 and 5% CO2.

Whole-cell patch-clamp recording

Whole-cell recordings were performed in a recording chamber on the stage of an Axioskop 2FS microscope with infrared differential interference contrast optics for visualization. eEPSCs were recorded from layer II/III neurons with HEKA EP10 amplifier (HEKA, Germany), and the stimulations were evoked in layer V of the IC by a bipolar tungsten stimulating electrode. The recording pipettes (3–5MΩ) were filled with the solution containing (in mM) 112 Cs-Gluconate, 5 TEA-Cl, 3.7 NaCl, 0.2 EGTA, 10 HEPES, 2 Mg-ATP, 0.1 Na3-GTP and 5 QX-314, which adjusted to pH 7.2 with CsOH and had osmolality of 290 mOsmol. Picrotoxin (PTX,100 μM, Tocris, UK) was presented to block the GABAA receptor-mediated inhibitory synaptic currents. NMDA receptor-mediated EPSCs were recorded at 30 mV by bathing with CNQX (20 mM, Tocris, UK). PEAQX (3 μM, Tocris, UK) was used as GluN2A receptor inhibitor and Ro25-6981 (3 μM, Tocris, UK) was used as GluN2B receptor. Data were discarded if access resistance changed > 15% during an experiment. Data were filtered at 1 kHz, and digitized at 10 kHz.

Statistical analysis

SPSS 26.0 software (IBM Corp., USA) was used for statistical analysis and Prism 8.3 software was used for mapping. The Shapiro-Wilk’s test was used to analyze data distribution, and Levene’s method was used to check homogeneity of variance. Two-tailed independent sample t-test or two-tailed independent sample rank sum test was used for comparison between two groups. Two-way ANOVA and Repeated measures ANOVA were used with Bonferroni or Least Significant Difference post hoc comparison when the same subjects were measured at three or more time points. When statistical conditions for repeated measures ANOVA were not met, K- independent samples rank sum test was used with Bonferroni post hoc comparison. P < 0.05 was considered statistically significant, and data were presented as mean ± standard error of the mean (SEM).

Results

Induced CM pain and anxiety behaviors after repeated infusions of IS

The detailed flow chart of study is shown in Fig. 1. There was no significant difference in the baseline periorbital mechanical threshold between the IS group and the PBS group (n(IS)=7 rats, n(PBS)=10 rats; Day 0: P=0.79; Fig. 2A). However, following two IS injections, the periorbital mechanical threshold in the IS group significantly decreased compared to the PBS group (Day 2: P<0.01). This trend continued from Day 3 to Day 14, with the IS group consistently exhibiting a significantly lower threshold than the PBS group ((Day 14: P<0.01; Fig. 2A). In the hot plate test, there was no significant difference in hind paw withdrawal latency between the IS and PBS groups (Day 0: P>0.99; Day 14: P=0.54; Fig. 2B).

Fig. 1
figure 1

Flow chart of the experimental outline

Full size image
Fig. 2
figure 2

Effects of repeated dural infusions of IS on pain and anxiety behaviors. A Decreases in periorbital mechanical threshold in rats were induced by repeated dural infusions of IS (IS: n=7 rats, PBS: n=10 rats; two-tailed independent sample rank sum test, ##P<0.01, compared with the PBS group). B Repeated IS injections did not alter thermal pain sensitivity in rat hind paws (n=10 rats/group; Day 2, Day 4, Day 8, Day 12 and Day 14, two-tailed independent sample t-test, Day 0, Day 6 and Day 10, two-tailed independent sample rank sum test, compared with the PBS group). C Samples of open field test in the IS and PBS rats at different time. D-G IS rats showed anxiety behaviors in the open field test (n=10 rats/group; two-tailed independent sample t-test, #P<0.05, ##P<0.01, compared with the PBS group; repeated measures ANOVA with Bonferroni post hoc comparison within IS group, *P<0.05, **P<0.01, compared with the baseline (Day 0)). (H) Samples of the EPM test in IS and PBS rats at different time. (I-L) IS rats showed anxiety behaviors in the EPM test, but no difference in total distance (n=10 rats/group; I, J (Day 0 and Day 14), K and L (Day 0), two-tailed independent sample t-test, #P<0.05, ##P<0.01, compared with the PBS group; J (Day 7) and L (Day 7 and Day 14), two-tailed independent sample rank sum test, # P<0.05, ##P<0.01, compared with the PBS group; I and L, repeated measures ANOVA with Least Significant Difference post hoc comparison within IS group, *P<0.05, **P<0.01, compared with the baseline (Day 0); J and K, k independent samples rank sum test with Bonferroni post hoc comparison within IS group, *P<0.05, **P<0.01, compared with the baseline (Day 0)). Data are presented as the mean ± SEM

Full size image

At the baseline of the open field test (n=10 rats/group), there was no significant difference between the IS group and the PBS group in the total distance (P=0.87; Fig. 2C and D), central distance (P=0.65; Fig. 2E), time in central area (P=0.41; Fig. 2F) and number of central area entries (P=0.70; Fig. 2G). On the Day 7, the significant reductions of the total distance (P=0.02), central distance (P=0.02), and time in the central area (P=0.03) were found when compared with the PBS group. On the Day 14, the IS group also showed a significant decrease in the total distance (P=0.01), central distance (P<0.01), time in the central area (P<0.01) and number of central area entries (P<0.01) compared with the PBS group (Fig. 2D-G). What’s more, the results within the IS group illustrated significant decrease at Day 7 and Day 14 when compared with baseline in total distance (P<0.01), central distance (Day 7: P=0.012, Day 14: P=0.02), and time in central area (P<0.01) (Fig. 2D-F). The number of central area entries only showed significant decreased on the Day 14 compared to the baseline (Day 7: P=0.13, Day 14: P=0.014; Fig. 2G).

What’s more, at baseline in the EPM test (n=10 rats/group), there was no statistical difference between the IS group and the PBS group in the total distance (P=0.95; Fig. 2H and I), open arms distance (P=0.55; Fig. 2J), open arms time (P=0.71; Fig. 2K) and number of entries into the open arms (P=0.61; Fig. 2L). On the Day 7, there was no difference between the IS group and the PBS group in the total distance (P=0.13; Fig. 2I), but the open arms distance (P<0.01), open arms time (P<0.01) and number of entries into the open arms (P=0.017) were significantly reduced compared to the PBS group (Fig. 2J-L). On the Day 14, the total distance (P=0.017), open arms distance (P<0.01), open arms time (P<0.01) and number of entries into the open arms (P=0.015) of the IS group were significantly reduced compared to the PBS group (Fig. 2I-L). Moreover, there were significant reductions in open arms distance (P<0.01), open arms time (P<0.01) and number of entries into the open arms (P<0.01) in the IS group on the Day 7 and Day 14 (Day 7: P=0.02, Day 14: P=0.04) compared to the baseline (Fig. 2J-L).

Activation of the IC in a rat model of CM

To identify whether the IC was activated in the migraine process, the immunofluorescence staining was used to detect the expression of c-Fos protein among the trigeminovascular system. We found that the positive cells of c-Fos protein in the ACC (n=5 rats/group; P<0.01), IC (n=5 rats/group; P=0.015) and TNC (n=4 rats/group; P=0.02) were significantly increased in the IS group compared with the PBS group (Fig. 3A and B).

Fig. 3
figure 3

Increased the number of c-Fos positive cells in the ACC, IC, TNC (Sp5c) of IS rats. A Left: Representative coronal section of ACC (top). Bar = 2000 μm. Representative immunofluorescence image for c-Fos in the ACC from PBS group (middle) and IS group (down). Bar = 100 μm. Middle: Representative coronal section of the IC (top). Bar = 2000 μm. Representative immunofluorescence image for c-Fos in the IC from PBS group (middle) and IS group (down). Bar = 100 μm. Right: Representative coronal section of the TNC (Sp5c) (top). Bar = 1000 μm. Representative immunofluorescence image for c-Fos in the TNC (Sp5c) from PBS group (middle) and IS group (down). Bar = 100 μm. The blue color is indicated for DAPI, red color is indicated for c-Fos and positive cells (colocalization) are indicated by white arrows. B Increased the number of c-Fos positive cells in the ACC of IS rats (n=5 rats/group; two-tailed independent sample t-test). C Increased the number of c-Fos positive cells in the IC of IS rats (n=5 rats/group; two-tailed independent sample t-test). D Increased the number of c-Fos positive cells in the TNC (Sp5c) of IS rats (n=4 rats/group; two-tailed independent sample rank sum test). All data are presented as the mean ± SEM (#P<0.05, ##P<0.01, IS vs. PBS)

Full size image

Long-term potentiation of excitatory synaptic transmission in the IC

The schematic diagram and representative recording diagram for spontaneous excitatory postsynaptic currents (sEPSCs) in the IC were shown in Fig. 4A- C. The frequency of sEPSCs was significantly increased in IS rats compared with PBS rats (n(IS)=12 neurons/5 rats, n(PBS)=11 neurons/6 rats; P=0.01; Fig. 4D left). While, the amplitude of sEPSCs did not show significant differences between two groups (n(IS)=12 neurons/5 rats, n(PBS)=11 neurons/7 rats; P=0.22; Fig. 4D right). Moreover, paired-pulse facilitation (PPF) is a transient form of plasticity commonly used as a measure of presynaptic function, in which the response to the second stimulus is enhanced as a result of residual calcium in the presynaptic terminal after the first stimulus [38]. In IS rats, PPF was observed at different stimulus intervals of 25, 50, 75, 100, 125 and 150 ms. At the stimulus intervals of 25 and 50 ms, there were significant reductions in PPF in the IC neurons compared with those from PBS rats (n(IS)=11 neurons/6 rats, n(PBS)=11 neurons/5 rats; 25ms intervals: P<0.01; 50ms intervals: P<0.01; Fig. 4E).

Fig. 4
figure 4

Increased synaptic transmission in the IC area of IS rats. A Schematic diagram showed the placement of stimulating and recording electrodes in the IC. rf, rhinal fissure. B Representative traces of the sEPSCs recorded in the IC neurons from IS and PBS rats. C Cumulative fraction of inter-event interval (left) and amplitude (right) of the sEPSCs in PBS rats and IS rats. D Statistic results of the frequency (IS: n=12 neurons/5 rats, PBS: n=11 neurons/6 rats; two-tailed independent sample t-test; left) and amplitude (IS: n=12 neurons/5 rats, PBS: n=11 neurons/6 rats; two-tailed independent sample t-test; right) of sEPSCs. (E) Representative traces with an interval of 50 ms recorded in the IC (top). Paired-pulse ratio (the ratio of EPSC2/EPSC1) was recorded at intervals of 25, 50, 75, 100, 125 and 150 ms from PBS and IS rats (IS: n=11 neurons/6 rats, PBS: n=11 neurons/5 rats; two-way ANOVA with Bonferroni post hoc; down). All data are presented as the mean ± SEM (##P<0.01, IS vs. PBS)

Full size image

To determine the receptor associated with the enhanced transmission in the IC of IS rats, we recorded the input (stimulation intensity)-output (EPSC amplitude) efficiency and I-V relationship of the NMDA receptor-mediated synaptic responses. The synaptic input-output curve in slices from IS rats was steeper than in those from the PBS group (n(IS)=10 neurons/6 rats, n(PBS)=11 neurons/5 rats; 4v intensity: P=0.04; 5v intensity: P<0.01; 6v intensity: P<0.01; Fig. 5A). Meanwhile, I-V curves of NMDA receptor-mediated EPSCs of the IC pyramidal neurons recorded at holding potentials ranging from − 80 to + 40 mV in PBS and IS rats (n(IS)=12 neurons/5 rats, n(PBS)=10 neurons/5 rats; -40mv: P<0.01; -20mv: P<0.01; 0mv: P<0.01; Fig. 5B). These results suggested that NMDA receptor-mediated synaptic transmission is enhanced in IS rats. Furthermore, we used PEAQX, a specific GluN2A subunit containing NMDA receptor antagonist, and Ro 25-6981, an antagonist of GluN2B, to investigate whether the ratio of the two receptor subtypes changed in the IC neurons between the IS and PBS groups. After recording the total NMDA receptor-mediated EPSCs in the IC neurons, GluN2A and GluN2B subunit-mediated currents were isolated by sequential application of the GluN2A-specific antagonist PEAQX and the GluN2B-specific antagonist Ro 25–6981 (Fig. 5C left). Within both IS group and PBS group, there was no difference in the GluN2A percentage in NMDA receptors-mediated currents in the IC neurons, while, the GluN2B percentage was higher in IS group than that in the PBS group (n(IS)=9 neurons/6 rats, n(PBS)=6 neurons/5 rats; GluN2A percentage: P=0.21; GluN2B percentage: P=0.018; Fig. 5C right). To further identify the above changes of the IC area after IS-modelling, the expression of GluN2B receptor in the IC area was detected. The expression of GluN2B, as well as its phosphorylation was higher in the IS group than that in the PBS group (n=5 rats/group; GluN2B: P<0.01; p-GluN2B-S1303: P<0.01; Fig. 5D-F).

Fig. 5
figure 5

Enhanced NMDA receptors-mediated currents and their expression in the IC. A The synaptic input-output curve in slices from IS rats was steeper than in those from PBS group (IS: n=10 neurons/6 rats, PBS: n=11 neurons/5 rats; two-way ANOVA with Bonferroni post hoc). B I-V curves of NMDAR-EPSCs of IC pyramidal neurons recorded at holding potentials ranging from − 80 to + 40 mV in PBS and IS rats (IS: n=12 neurons/5 rats, PBS: n=10 neurons/5 rats; two-way ANOVA with Bonferroni post hoc). C A timeline plot of one representative neuron in IC showing the contribution of NMDA GluN2A and GluN2B -mediated currents (left). PEAQX (0.4 μM): selective GluN2A antagonist, Ro25-6981 (3 μM): selective GluN2B antagonist. Summarized data showing the contribution of GluN2A (two-tailed independent sample t-test) and GluN2B (two-tailed independent sample rank sum test) -mediated currents in IC neurons (IS: n=9 neurons/6 rats, PBS: n=6 neurons/5 rats; right). D Representative western blotting for GluN2B and p-GluN2B-S1303 in the IC from IS and PBS rats. E The total protein levels of GluN2B, p-GluN2B-S1303 significantly enhanced in IS rats (n=5 rats/group; two-tailed independent sample t-test). F The phosphorylation level of GluN2B, p-GluN2B-S1303, significantly enhanced in IS rats (n=5 rats/group; two-tailed independent sample t-test). All data are presented as the mean ± SEM (#P<0.05, ##P<0.01, IS vs. PBS)

Full size image

AC1 is required for increases in CGRP and anxiety behaviors

Both immunofluorescence staining and western blotting tests showed that the expression of CGRP in the IC area increased among rats suffering CM (immunofluorescence staining: n=5 rats/group, P<0.01, Fig. 6A, B; western blotting tests: n=5 rats/group, P<0.01, Fig. 6C). The human-used AC1 inhibitor, hNB001, was applied intraperitoneally into the IS group, and the following western blotting results showed that the expression of CGRP in the IC of i.p. hNB001 group were significantly decreased compared with the control (n=5 rats/group; P<0.01; Fig. 6D). Besides, the periorbital mechanical threshold in the i.p. hNB001 group was significantly higher than that in the i.p. NS group after once injection (n=8 rats/group; Day 15: P=0.014; Fig. 6E). From Day 16 to Day 17, the threshold of the i.p. hNB001 group continued to increase and was significantly higher than that of the i.p. NS group (Day 16: P<0.01; Day 17: P<0.01; Fig. 6E). Furthermore, the effects of intraperitoneal injection of hNB001 on anxiety behaviors were detected by the open field test and the EPM test (Fig. 6F and G). In the open field test on Day 17, although there was no difference in total distance (n=6 rats/group; P=0.11; Fig. 6H), the central distance of the i.p. hNB001 group was significantly more than that of the i.p. NS group (P<0.01; Fig. 6I). Within the i.p. hNB001 group, the central distance on Day 17 was significantly more than that on Day 14 (P<0.01; Fig. 6I). For EPM test, there was no difference in total distance (n=6 rats/group; P=0.25; Fig. 6J), but the open arms distance (P<0.01; Fig. 6K) of the i.p. hNB001 group was significantly longer than that of the i.p. NS group on Day 17. After three times of intraperitoneal injection of hNB001, the above parameters were significantly increased compared with Day 14 (P=0.016; Fig. 6K).

Fig. 6
figure 6

AC1 is required for increases in CGRP and anxiety behaviors. A Representative immunofluorescence image for CGRP in the IC from PBS group (left) and IS group (right). Bar = 50 μm. The blue color is indicated for DAPI, red color is indicated for CGRP and positive cells (colocalization) are indicated by white arrows. B Increased the number of CGRP positive cells in the IC of IS rats (n=5 rats/group; two-tailed independent sample t-test). C Representative western blotting band for CGRP in the IC from IS and PBS groups(left). The total protein levels of CGRP significantly enhanced in the IC of IS group (n=5 rats/group; two-tailed independent sample t-test; right). D Representative western blotting band for CGRP in the IC from i.p. NS and i.p. hNB001 groups (left). The total protein levels of CGRP significantly reduced in the IC of i.p. hNB001 group (n=5 rats/group; two-tailed independent sample t-test; right). E The hNB001 reversed the decrease in periorbital mechanical threshold in the IS rats (n=8 rats/group; two-tailed independent sample rank sum test). The black arrow indicates the first intraperitoneal injection of hNB001. F Samples of open field test from IS rats that received NS or hNB001 injections. G Samples of EPM test from IS rats that received NS or hNB001 injections. H, I In the open field test, hNB001 increased the distance traveled in the central area of IS rats, but had no effect on the total distance traveled (n=6 rats/group; two-tailed independent sample t-test). J, K In the EPM test, hNB001 increased the distance traveled in the open arms of IS rats, but had no effect on the total distance traveled (n=6 rats/group; two-tailed independent sample t-test). All data are presented as the mean ± SEM (#P<0.05, ##P<0.01, IS vs. PBS or i.p. hNB001 vs. i.p. NS; *P<0.05, **P<0.01, compared with Day 14)

Full size image

Inhibition of AC1 in the IC alleviated migraine pain and anxiety behaviors

After microinjecting hNB001 into the bilateral IC area (Fig. 7A), the periorbital mechanical threshold of the hNB001 group significantly increased starting from the first injection (n=6 rats/group; Day 15: P<0.01; Fig. 7B). Next, anxiety-like behaviors were detected. The open field test showed no differences on total distance (n=6 rats/group; P=0.99; Fig. 7C, D), but the central distance of the hNB001 group was significantly increased compared with NS injections (P<0.01; Fig. 7C-E). The EPM results indicated that after hNB001 microinjection in the IC area, there was no difference in total distance (n=6 rats/group; P=0.26; Fig. 7F, G), but the open arms distance increased when compared with the NS group (P=0.02; Fig. 7F-H).

Fig. 7
figure 7

Inhibition of AC1 in the IC alleviated migraine pain and anxiety behaviors. A Schematic diagram showed the placement of hNB001 microinjection in the IC (left), and microscopy images of coronal rat brain tissue section after prussian blue staining showing the placement (white arrow, right). Bar=100 μm. B The hNB001 reversed the decrease in periorbital mechanical threshold in the IS rats (n=6 rats/group; two-tailed independent sample rank sum test). The black arrow indicates the first hNB001 administration. C Samples of the open field test from IS rats that received NS or hNB001 microinjections. D, E In the open field test, hNB001 increased the distance traveled in the central area of IS rats, but had no effect on the total distance traveled (n=6 rats/group; two-tailed independent sample t-test). F Samples of EPM test from IS rats that received NS or hNB001 microinjections. G, H In the EPM test, hNB001 increased the distance traveled in the open arms of IS rats, but had no effect on the total distance traveled (n=6 rats/group; two-tailed independent sample t-test). All data are presented as the mean ± SEM (**P<0.01, compared with Day 14; #P<0.05, ##P<0.01, hNB001 vs. NS)

Full size image

Discussion

Here, we find that dural repeated IS stimulations in rats induce migraine-like symptoms and related anxiety behaviors. The integrated data of biochemical, physiological and behavioral tests demonstrate that the IC area is activated under the pathological conditions of chronic migraine. The excitatory transmission in the IC enhanced, and the NMDA receptor mediated responses, especially the GluN2B-contaning NMDA receptor mediated responses increased. Furthermore, a selective AC1 inhibitor, hNB001, attenuated the increased expression of CGRP in the IC, and applied locally or intraperitoneally of hNB001 alleviate pain threshold as well as anxiety behaviors in rats suffering CM.

Activation of insula after IS-induced migraine condition

Based on Moskowitz and Ashina’s proposals, the initiation of migraine depends on activation and sensitization of first-order trigeminovascular neurons and the afferent fibers of these neurons innervate the meninges and its vessels [2, 39]. Thus, according to previous researches, continuous dural infusion of IS were used to induce meningeal nociception and activate the trigeminal neurovascular pathway, resulting in the orofacial allodynia [35, 40]. A significant decrease in the periorbital mechanical threshold is observed in rats after continuous IS stimulations. Compared with our previous studies, we find that the IS injections for 14 days are sufficient to induce stable pain status in adult rats [40, 41]. At the same time, the expression of c-Fos, a reliable marker of neuronal activation after stimulation [42] , and CGRP, a crucial biomarker in migraine progression [43], are increased in the IC area compared with control group, which demonstrated the IC is involved in processing migraine modeling in the rats. Concurrently, through the open field test and the EPM test, we observe a significant increase in anxiety-like negative emotions in IS rats on Day 7 and Day 14. Since the periorbital mechanical threshold is decreased from twice injections of IS, it indicates the co-occurrence of migraine and its related anxiety behaviors. These results are consistent with clinical observations that migraine patients often suffer from anxiety and/or depression [44, 45].

Insular excitability and chronic migraine

The cumulative studies from human and animal studies suggest that migraine is a disease of brain dysfunction, including increased cortical excitability, structural and/or functional changes in the brainstem as well as multiple brain regions [46]. Previous studies indicate that glutamate significantly influences the regulation of pain and negative emotions [17, 47, 48]. It has been shown that glutamate levels rise in the cerebrospinal fluid of migraine patients during and between attacks [49,50,51]. In our study, we find that the excitatory transmission in the IC of migraine rats enhanced, and the NMDA receptor mediated responses, especially the GluN2B-contaning NMDA receptor mediated responses increased. Some studies have shown that the phosphorylation of NMDA GluN2B receptors contributes to cortical excitation and chronic pain of neuropathic and visceral pain [16, 52]. In this study, we reveal the expression and phosphorylation of GluN2B-contaning NMDA receptor are upregulated in the IC of rats suffering CM, which are coincident with the research about the ACC area in CM models [33]. These results indicate that both IC and ACC area may share the similar signaling pathways in regulating migraine processing.

The role of AC1-involved signaling pathway of insula in the chronic migraine

Previous studies have demonstrated that AC1 is primarily expressed in neurons, and no AC1 gene expression was found in heart, liver, or kidney cells [53, 54]. Morphological studies have proved that in the forebrain, there is no detectable differences of the expression of AC1 in the ACC, IC, somatosensory cortex, thalamus, spinal dorsal horn, and dorsal root ganglia [55, 56]. AC1 has been shown in our previous studies to be involved in the regulation of synaptic excitability as a critical downstream regulatory molecule of the NMDA receptor pathway [16, 53, 57]. Here, the intraperitoneal injection of hNB001 is used as an approach of peripheral application. It shows that hNB001 could alleviate orofacial allodynia as well as anxiety-like behavior by decreasing the expression of CGRP in the IC. Besides, hNB001 is a small molecule substance. Both of these indicate that hNB001 could cross the blood -brain barrier. While, we cannot rule out the possibility that peripheral application of hNB001 could also affect brain regions (ACC, amygdala, etc.) that expressing AC1 and modulating pain as well as its related emotions. Thus, the microinjection of hNB001 into the IC is further applied to show the direct effect of the IC area in migraine progression. The data shows similar analgesic and anxiolytic effects, which further support that the hNB001 could pass the blood-brain barrier and exert its effect in the brain. These also have been reported in a few previous studies[58, 59]. The elevated expression of CGRP in the IC is attenuated after intraperitoneally and locally treating with hNB001 (Fig. 6 and Fig. S3), which indicates that regulation of AC1 could influence the expression of CGRP, leading to the pain management. These demonstrate that AC1-dependent IC plasticity contributes to chronic migraine.

Clinical implications

Nowadays, CGRP receptor antagonists, anti-CGRP antibodies and anti-CGRP receptor antibodies have proved effective for relieving migraine symptoms, strongly supporting that CGRP has a major role in migraine pathophysiology [2, 60,61,62] .However, use of monoclonal antibodies against CGRP or its receptor still has potential immunogenicity and theoretical concerns of cardiovascular safety and liver toxicity, which limited the clinical application [61]. Some CGRP or CGRP receptors monoclonal antibodies are difficult to penetrate the blood-brain barrier and need to be injected in time. This method of administration creates inconvenience and risks during the injection process [61, 63]. However, the hNB001 we used in the current study can be absorbed orally and has exhibited notable analgesic effects in other animal models, such as cancer pain, neuropathic pain and phantom limb pain, with little effect on physiological pain perception, cognition, and motor function. Particularly, it does not show obvious addiction [64,65,66]. Besides, the results of a clinical phase I study have been published, confirming the safety and good tolerance of hNB001 in human [67]. Consequently, the hNB001 has a potential prospect for application in treating migraine in the future.

Limitations

Although our study provides strong evidence that the IC is involved in processing of migraine and related anxiety behaviors, there are still some limitations needed further exploration. For instance, the only male rats were used in the current study in order to exclude the effect of estrogen fluctuations. Previous studies found that the majority of changes in the expression of CGRP and its receptor were present in both the IS and PBS-control treated male and female rats and the changes might be much more significant within female groups than in male groups [68]. Considering the present results have already shown that male rats have significant differences among groups, the female rats are not added in view of animal welfare and ethics. Secondly, the upstream and downstream molecular signals of AC1 are still unclear and the functional connections between the IC and other brain regions also require further investigations. Lastly, the methods and timing of hNB001 administrations could also be further explored to identify an optimal mode.

Conclusions

In summary, our findings reveal that the GluN2B receptor and its downstream molecule AC1 in the IC area play crucial roles in chronic migraine, and inhibition of AC1 can effectively alleviate pain and related anxiety behaviors. AC1 may become a potential target for the treatment of migraine in the future.

Fundings

All studies were funded by the National Natural Science Foundation of China (82101288, YLL) and the National Natural Science Foundation of China (81901134, HX).

Availability of data and materials

No datasets were generated or analysed during the current study.

Abbreviations

AC1:

adenylate cyclase 1

ACC:

anterior cingulate cortex

ACSF:

artificial cerebrospinal fluid

CGRP:

calcitonin gene-related peptide

CM:

chronic migraine

CNS:

central nervous system

DAPI:

4’,6-diamidino-2-phenylindole

EPM:

elevated plus maze

EPSCs:

excitatory postsynaptic currents

IC:

insular cortex

IS:

inflammatory soup

NMDA:

N-methyl-D-aspartate

NS:

normal saline

PBS:

phosphate buffered saline

PFA:

paraformaldehyde

PLA:

People’s Liberation Army

PPF:

paired-pulse facilitation

PTX:

picrotoxin

PVDF:

polyvinyl difluoride

SEM:

standard error of the mean

sEPSCs:

spontaneous excitatory postsynaptic currents

TNC:

trigeminal nucleus caudalis

References

  1. Cohen SP, Vase L, Hooten WM (2021) Chronic pain: an update on burden, best practices, and new advances. The Lancet 397(10289):2082–2097

    Article  Google Scholar 

  2. Ashina M, Ropper AH (2020) Migraine. New England Journal of Medicine 383(19):1866–1876

    Article  CAS  PubMed  Google Scholar 

  3. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. The Journal of Headache and Pain 21(1):1–4

    Article  Google Scholar 

  4. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N et al (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 18(5):459–480

    Article  Google Scholar 

  5. Fitzcharles M-A, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W (2021) Nociplastic pain: towards an understanding of prevalent pain conditions. The Lancet 397(10289):2098–2110

    Article  Google Scholar 

  6. Gold MS, Gebhart GF (2010) Nociceptor sensitization in pain pathogenesis. Nature Medicine 16(11):1248–1257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gogolla N (2017) The insular cortex. Curr Biol 27(12):R580–R586

    Article  CAS  PubMed  Google Scholar 

  8. Labrakakis C (2023) The Role of the Insular Cortex in Pain. International Journal of Molecular Sciences 24(6):5736

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Indovina I, Bosco G, Riccelli R, Maffei V, Lacquaniti F, Passamonti L, Toschi N (2020) Structural connectome and connectivity lateralization of the multimodal vestibular cortical network. NeuroImage 222:117247

    Article  PubMed  Google Scholar 

  10. Ferrier J, Bayet-Robert M, Dalmann R, El Guerrab A, Aissouni Y, Graveron-Demilly D et al (2015) Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception. J Neurosci 35(50):16418–16430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Qiu S, Zhang M, Liu Y, Guo Y, Zhao H, Song Q et al (2014) GluA1 phosphorylation contributes to postsynaptic amplification of neuropathic pain in the insular cortex. J Neurosci 34(40):13505–13515

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kikkert S, Mezue M, O’Shea J, Henderson Slater D, Johansen-Berg H, Tracey I, Makin TR (2019) Neural basis of induced phantom limb pain relief. Ann Neurol 85(1):59–73

    Article  PubMed  PubMed Central  Google Scholar 

  13. Liu MG, Kang SJ, Shi TY, Koga K, Zhang MM, Collingridge GL et al (2013) Long-term potentiation of synaptic transmission in the adult mouse insular cortex: multielectrode array recordings. J Neurophysiol 110(2):505–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu M-G, Zhuo M (2014) Loss of long-term depression in the insular cortex after tail amputation in adult mice. Molecular Pain 10:1744–8069

    Article  Google Scholar 

  15. Zhuo M (2016) Contribution of synaptic plasticity in the insular cortex to chronic pain. Neuroscience 338:220–229

    Article  CAS  PubMed  Google Scholar 

  16. Qiu S, Chen T, Koga K, Guo Y-y, Xu H, Song Q et al (2013) An Increase in Synaptic NMDA Receptors in the Insular Cortex Contributes to Neuropathic Pain. Science Signaling 6(275):ra34

    Article  PubMed  Google Scholar 

  17. Wu L-J, Toyoda H, Zhao M-G, Lee Y-S, Tang J, Ko SW et al (2005) Upregulation of Forebrain NMDA NR2B Receptors Contributes to Behavioral Sensitization after Inflammation. J Neurosci 25(48):11107–11116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Xu H, Wu L-J, Wang H, Zhang X, Vadakkan KI, Kim SS et al (2008) Presynaptic and Postsynaptic Amplifications of Neuropathic Pain in the Anterior Cingulate Cortex. J Neurosci 28(29):7445–7453

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bliss TV, Collingridge GL, Kaang BK, Zhuo M (2016) Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Nat Rev Neurosci 17(8):485–96

    Article  CAS  PubMed  Google Scholar 

  20. Li X-Y, Ko H-G, Chen T, Descalzi G, Koga K, Wang H et al (2010) Alleviating Neuropathic Pain Hypersensitivity by Inhibiting PKMζ in the Anterior Cingulate Cortex. Science 330(6009):1400–1404

    Article  CAS  PubMed  Google Scholar 

  21. Zhuo M (2020) Cortical plasticity as synaptic mechanism for chronic pain. J Neural Transmiss 127(4):567–573

    Article  Google Scholar 

  22. Zhuo M (2019) Long-term cortical synaptic changes contribute to chronic pain and emotional disorders. Neurosci Letters 702:66–70

    Article  CAS  Google Scholar 

  23. Zhang M-M, Geng A-Q, Chen K, Wang J, Wang P, Qiu X-T et al (2022) Glutamatergic synapses from the insular cortex to the basolateral amygdala encode observational pain. Neuron 110(12):1993-2008.e6

    Article  CAS  PubMed  Google Scholar 

  24. Schwedt TJ, Schlaggar BL, Mar S, Nolan T, Coalson RS, Nardos B et al (2013) Atypical Resting-State Functional Connectivity of Affective Pain Regions in Chronic Migraine. J Head Face Pain 53(5):737–751

    Article  Google Scholar 

  25. Maleki N, Barmettler G, Moulton EA, Scrivani S, Veggeberg R, Spierings ELH et al (2015) Female migraineurs show lack of insular thinning with age. Pain 156(7):1232–1239

    Article  PubMed  PubMed Central  Google Scholar 

  26. Jia Z, Yu S, Tang W, Zhao D (2020) Altered functional connectivity of the insula in a rat model of recurrent headache. Molecular Pain 16:1–18

    Article  CAS  Google Scholar 

  27. Gorka SM, Young CB, Klumpp H, Kennedy AE, Francis J, Ajilore O et al (2019) Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: a randomized trial. Neuropsychopharmacol 44(9):1639–1648

    Article  Google Scholar 

  28. Nicolas C, Ju A, Wu Y, Eldirdiri H, Delcasso S, Couderc Y et al (2023) Linking emotional valence and anxiety in a mouse insula-amygdala circuit. Nature Communications 14(1):5073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol, Neurosurg Psychiatry 87(7):741–749

    Article  PubMed  Google Scholar 

  30. Alwhaibi M, Alhawassi TM (2020) Humanistic and economic burden of depression and anxiety among adults with migraine: A systematic review. Depress Anxiety 37(11):1146–1159

    Article  PubMed  Google Scholar 

  31. Liu Y, Chen QY, Lee JH, Li XH, Yu S, Zhuo M (2020) Cortical potentiation induced by calcitonin gene-related peptide (CGRP) in the insular cortex of adult mice. Molecular Brain 13:1–10

    Article  PubMed  PubMed Central  Google Scholar 

  32. Li X-H, Matsuura T, Liu R-H, Xue M, Zhuo M (2019) Calcitonin gene-related peptide potentiated the excitatory transmission and network propagation in the anterior cingulate cortex of adult mice. Molecular Pain 15:1–14

    Article  Google Scholar 

  33. Liu RH, Zhang M, Xue M, Wang T, Lu JS, Li XH et al (2023) Inhibiting neuronal AC1 for treating anxiety and headache in the animal model of migraine. iScience 26(6):106790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Miao S, Tang W, Li H, Li B, Yang C, Xie W et al (2022) Repeated inflammatory dural stimulation-induced cephalic allodynia causes alteration of gut microbial composition in rats. J Headache Pain 23(1):71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Oshinsky ML, Gomonchareonsiri S (2007) Episodic Dural Stimulation in Awake Rats: A Model for Recurrent Headache. Headache 47(7):1026–1036

    Article  PubMed  PubMed Central  Google Scholar 

  36. Han X, Ran Y, Su M, Liu Y, Tang W, Dong Z, Yu S (2017) Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats. Molecular Pain 13:1–10

    Article  Google Scholar 

  37. Nakaya Y, Yamamoto K, Kobayashi M (2023) Descending projections from the insular cortex to the trigeminal spinal subnucleus caudalis facilitate excitatory outputs to the parabrachial nucleus in rats. Pain 164(3):e157–e173

    Article  CAS  PubMed  Google Scholar 

  38. Müller M, Felmy F, Schneggenburger R (2008) A limited contribution of Ca2+ current facilitation to paired-pulse facilitation of transmitter release at the rat calyx of Held. J Physiol 586(22):5503–5520

    Article  PubMed  PubMed Central  Google Scholar 

  39. Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16(2):157–168

    Article  CAS  PubMed  Google Scholar 

  40. Wu H, Dong Z, Liu Y, Zhang Q, Zhang M, Hu G et al (2023) Temporal alterations of pituitary adenylate cyclase activating polypeptide and its receptors in a rat model induced by recurrent chemical stimulations: Relevant to chronic migraine. Molecular Pain 19:1–19

    Article  CAS  Google Scholar 

  41. Zhang M, Liu Y, Hu G, Kang L, Ran Y, Su M, Yu S (2020) Cognitive impairment in a classical rat model of chronic migraine may be due to alterations in hippocampal synaptic plasticity and N-methyl-D-aspartate receptor subunits. Molecular Pain 16:1–11

    Article  Google Scholar 

  42. Joo J-Y, Schaukowitch K, Farbiak L, Kilaru G, Kim T-K (2015) Stimulus-specific combinatorial functionality of neuronal c-fos enhancers. Nature Neuroscience 19(1):75–83

    Article  PubMed  PubMed Central  Google Scholar 

  43. Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565–1644

    Article  CAS  PubMed  Google Scholar 

  44. George A, Minen MT (2023) Episodic Migraine and Psychiatric Comorbidity: A Narrative Review of the Literature. Curr Pain Headache Rep 27(9):461–469

    Article  PubMed  Google Scholar 

  45. Henningsen P, Hausteiner-Wiehle C, Häuser W (2022) Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review. Headache 62(10):1272–1280

    Article  PubMed  Google Scholar 

  46. Su M, Yu S (2018) Chronic migraine: A process of dysmodulation and sensitization. Molecular Pain 14:1–10

    Article  Google Scholar 

  47. Li X-H, Chen Q-Y, Zhuo M (2020) Neuronal Adenylyl Cyclase Targeting Central Plasticity for the Treatment of Chronic Pain. Neurotherapeutics 17(3):861–873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al (2010) Glutamate Receptor Ion Channels: Structure, Regulation, and Function. Pharmacol Rev 62(3):405–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M (1993) Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 13:89–93

    Article  PubMed  Google Scholar 

  50. Vieira DS, d, Naffah-Mazzacoratti M d G, Zukerman E, Soares C A S, Cavalheiro E A and Peres M F P, (2007) Glutamate Levels in Cerebrospinal Fluid and Triptans Overuse in Chronic Migraine. Headache 47(6):842–847

    Article  PubMed  Google Scholar 

  51. Peres MFP, Zukerman E, Soares CAS, Alonso EO, Santos BFC, Faulhaber MHW (2016) Cerebrospinal Fluid Glutamate Levels in Chronic Migraine. Cephalalgia 24(9):735–739

    Article  Google Scholar 

  52. Yang L-k, Lu L, Feng B, Wang X-s, Yue J, Li X-b et al (2020) FMRP acts as a key messenger for visceral pain modulation. Molecular Pain 16:1–12

    Article  CAS  Google Scholar 

  53. Zhuo M (2012) Targeting neuronal adenylyl cyclase for the treatment of chronic pain. Drug Discovery Today 17(11–12):573–582

    Article  CAS  PubMed  Google Scholar 

  54. Wang H, Xu H, Wu LJ, Kim SS, Chen T, Koga K et al (2011) Identification of an Adenylyl Cyclase Inhibitor for Treating Neuropathic and Inflammatory Pain. Sci Transl Med 3(65):65ra3

    Article  CAS  PubMed  Google Scholar 

  55. Devasani K, Yao Y (2022) Expression and functions of adenylyl cyclases in the CNS. Fluids Barriers CNS 19(1):23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Wei F, Qiu C-S, Kim SJ, Muglia L, Maas JW, Pineda VV et al (2002) Genetic Elimination of Behavioral Sensitization in Mice Lacking Calmodulin-Stimulated Adenylyl Cyclases. Neuron 36(4):713–726

    Article  CAS  PubMed  Google Scholar 

  57. Zhuo M (2008) Cortical excitation and chronic pain. Trends in Neurosciences 31(4):199–207

    Article  CAS  PubMed  Google Scholar 

  58. Liu R-H, Zhang M, Xue M, Wang T, Lu J-S, Li X-H et al (2023) Inhibiting neuronal AC1 for treating anxiety and headache in the animal model of migraine. iScience 26(6):106790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wang W, Chen Q-Y, Zhao P, Zhong J, Wang Y, Li X et al (2022) Human safety study of a selective neuronal adenylate cyclase 1 inhibitor NB001 which relieves the neuropathic pain and blocks ACC in adult mice. Molecular Pain 18:17448069221089596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G (2019) Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia 39(14):1827–1837

    Article  PubMed  Google Scholar 

  61. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ et al (2021) Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397(10283):1505–1518

    Article  PubMed  Google Scholar 

  62. Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol 14(6):338–350

    Article  CAS  PubMed  Google Scholar 

  63. Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501–514

    Article  PubMed  PubMed Central  Google Scholar 

  64. Liu S, b, Wang X s, Yue J, Yang L, Li X h, Hu L n, et al (2020) Cyclic AMP-dependent positive feedback signaling pathways in the cortex contributes to visceral pain. J Neurochem 153(2):252–263

    Article  CAS  PubMed  Google Scholar 

  65. Kang W-b, Yang Q, Guo Y-y, Wang L, Wang D-s, Cheng Q et al (2016) Analgesic effects of adenylyl cyclase inhibitor NB001 on bone cancer pain in a mouse model. Molecular Pain 12:1–9

    Article  CAS  Google Scholar 

  66. Wang H, Xu H, Wu LJ, Kim SS, Chen T, Koga K et al (2011) Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain. Sci Trans Med 3(65):ra3

    Article  Google Scholar 

  67. Wang W, Chen Q-Y, Zhao P, Zhong J, Wang Y, Li X et al (2022) Human safety study of a selective neuronal adenylate cyclase 1 inhibitor NB001 which relieves the neuropathic pain and blocks ACC in adult mice. Molecular Pain 18:1–15

    Article  Google Scholar 

  68. Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE, Berman NEJ (2011) Sex Differences in Behavior and Expression of CGRP-Related Genes in a Rodent Model of Chronic Migraine. Headache 51(5):674–692

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Authors and Affiliations

  1. Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China

    Yang Li, Chenhao Li, Jingrui Mao, Wenwen Zhang, Xun Han, Zhao Dong, Ruozhuo Liu, Wenjing Tang, Shengyuan Yu & Yinglu Liu

  2. Medical School of Chinese PLA, Beijing, China

    Yang Li, Chenhao Li & Jingrui Mao

  3. School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian Province, China

    Qi-Yu Chen & Min Zhuo

  4. Zhuomin Institute of Brain Research, Qingdao, Shandong Province, China

    Qi-Yu Chen, Shun Hao & Min Zhuo

  5. School of Medicine, Nankai University, Tianjin, China

    Wenwen Zhang

  6. Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

    Min Zhuo

Authors
  1. Yang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chenhao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi-Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shun Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingrui Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenwen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xun Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhao Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ruozhuo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wenjing Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Min Zhuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shengyuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yinglu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: YLL, SYY, MZ; Methodology and investigation: YL performed most of the behavior and western blot experiments. CHL performed most of immunofluorescence studies. QYC, SH and YLL were responsible for electrophysiological experiments. JRM and WWZ performed some of behavior and biochemical studies. YL, XH and DZ pooled the data for analysis. RZL, WJT and DFZ were responsible for optimizing the pictures; Funding acquisition: YLL, XH; Supervision: YLL, SYY, MZ; Writing – original draft: YL, YLL, QYC; Writing – review & editing: YL, YLL, SYY, MZ. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Min Zhuo, Shengyuan Yu or Yinglu Liu.

Ethics declarations

Ethics approval and consent to participate

The experimental procedures were approved by the Institutional Animal Care and Use Committee, Chinese People’s Liberation Army (PLA) General Hospital, following the Regulations for the Administration of Affairs Concerning Experimental Animals.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

 Figure S1. The raw western blotting images for the GluN2B and p-GluN2B-S1303 in the IC from the IS and PBS rats (n=5 rats/group). 

Additional file 2: Figure S2.  

The raw western blotting images for CGRP among different groups. (A) The raw western blotting images for CGRP in the IC from the IS and PBS rats (n=5 rats/group). (B) The raw western blotting images for CGRP in the IC from the i.p. hNB001 and i.p. NS rats (n=5 rats/group). (C) The raw western blotting images for CGRP in the IC from the hNB001 and NS rats (n=5 rats/group).

Additional file 3: Figure S3. 

Microinjection of the hNB001 in the IC decreased the expression of CGRP in the IC. (A) Representative western blotting band for CGRP in the IC from the NS and hNB001 groups. (B) The total protein levels of CGRP significantly reduced in the IC of the hNB001 group (n=5 rats/group; two-tailed independent sample t-test; P<0.01). All data are presented as the mean ± SEM (##P<0.01, hNB001 vs. NS).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Li, C., Chen, QY. et al. Alleviation of migraine related pain and anxiety by inhibiting calcium-stimulating AC1-dependent CGRP in the insula of adult rats. J Headache Pain 25, 81 (2024). https://doi.org/10.1186/s10194-024-01778-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s10194-024-01778-3

Keywords

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us